Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).Martín Zarbá, Daniel Yick Chin Heng, Naveen S. Basappa et al.|Journal of Clinical Oncology|2024Cited by 10
Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).Audreylie Lemelin, Daniel Yick Chin Heng, Kosuke Takemura et al.|Journal of Clinical Oncology|2023Cited by 3